TSHA
Taysha Gene Therapies, Inc. · Healthcare · Market cap $1.7B
Insiders sold $2.1M net in the last 90 days ·1 seller, 0 buyers· 2 of 2 sales under Rule 10b5-1 plans· latest Form 4 filed Jul 10, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.7M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Jul 10, 2026
Nagendran Sukumar
Taysha Gene Therapies, Inc. (TSHA) has 14 SEC Form 4 filings (25 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 10, 2026.
Inside the rolling window, 3 insiders at Taysha Gene Therapies, Inc. reported no open-market purchases and 12 open-market sales totaling $6.7M. The most active filer is President and Head of R&D Nagendran Sukumar with 7 filings. Insiders have net sold $5.0M over the trailing 6 months. The most recent open-market filing is a sale of 200,000 shares by President and Head of R&D Nagendran Sukumar, dated Jul 10, 2026, worth $1.2M.
- Industry:Biotechnology
- CEO:Sean Nolan
- Employees:99
- HQ:Dallas, TX, US
- IPO:2020-09-24
| Source | |||||||
|---|---|---|---|---|---|---|---|
| President and Head of R&D | Sale | 200,000 | $1.2M | Jul 10 | -18.6% | SEC ↗ | |
| President and Head of R&D | Sale | 200,000 | $892K | Apr 13 | +16.7% | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,655 | $7K | Feb 6 | +11.9% | SEC ↗ | |
| President and Head of R&D | Sale | 89,132 | $423K | Jan 27 | +8.4% | SEC ↗ | |
| President and Head of R&D | Sale | 26,918 | $124K | Jan 27 | +8.4% | SEC ↗ | |
Alam KamranFirst filing | CHIEF FINANCIAL OFFICER | Sale | 78,968 | $375K | Jan 27 | +8.4% | SEC ↗ |
Alam KamranFirst filing | CHIEF FINANCIAL OFFICER | Sale | 23,849 | $110K | Jan 27 | +8.4% | SEC ↗ |
Nolan Sean P.First filing | Chief Executive Officer | Sale | 136,789 | $650K | Jan 27 | +8.4% | SEC ↗ |
Nolan Sean P.First filing | Chief Executive Officer | Sale | 41,312 | $190K | Jan 27 | +8.4% | SEC ↗ |
| President and Head of R&D | Sale | 200,000 | $942K | Jan 14 | +2.4% | SEC ↗ | |
Nagendran SukumarFirst filing | President and Head of R&D | Sale | 110,125 | $523K | Dec 1 | — | SEC ↗ |
Nagendran SukumarFirst filing | President and Head of R&D | Sale | 260,047 | $1.2M | Dec 1 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does TSHA have?
Taysha Gene Therapies, Inc. (TSHA) has 14 SEC Form 4 filings (25 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Jul 10, 2026.
When was the most recent SEC Form 4 filing for TSHA?
The most recent Form 4 filing for TSHA on Tracefour is dated Jul 10, 2026.
Who is the most active insider at TSHA?
The most active SEC Form 4 filer at TSHA in the rolling window is President and Head of R&D Nagendran Sukumar, with 7 filings.
What is the net insider flow at TSHA over the last 6 months?
Over the trailing 180 days, insiders at TSHA have net sold $5.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at TSHA in the current window?
Inside the rolling window, insiders at TSHA bought $0 and sold $6.7M based on SEC Form 4 filings.
Can I get alerts for TSHA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Taysha Gene Therapies, Inc. (TSHA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Taysha Gene Therapies, Inc. is in the Healthcare sector.